New Technology Promises More Affordable and Accessible Cancer Immunotherapy

WisBusiness: Exact Sciences plans to introduce an updated version of its Oncodetect test next year, improving its ability to identify circulating cancer DNA - Wisconsin Technology Council

The Madison diagnostics business yesterday announced the “next-generation” version of its molecular residual disease is currently being tested across multiple types of solid tumors. It will be able to track up to 5,000 patient-specific cancer variants, the release notes, boasting an “ultra low” detection threshold. The updated version of Oncodetect is based in part on

New Technology Promises More Affordable and Accessible Cancer Immunotherapy

In the rapidly evolving landscape of cancer treatment, CAR T cell immunotherapy stands out as one of the most groundbreaking advancements, harnessing the body’s own immune system to target and eradicate malignant cells. This innovative therapy modifies a patient’s T cells—critical white blood cells responsible for immune defense—empowering them to identify and destroy tumors. While CAR T cell therapy has demonstrated remarkable success against b…